Which has higher earnings and valuation, PHVS or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is PHVS or IMVT more profitable?

Pharvaris' return on equity of -61.40% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Immunovant N/A -69.59% -62.49%

Does the media prefer PHVS or IMVT?

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. Immunovant's average media sentiment score of 1.29 beat Pharvaris' score of 0.94 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PCVX or PHVS?

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is PCVX or PHVS more profitable?

Vaxcyte's return on equity of -37.56% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Pharvaris N/A -61.40% -56.00%

Does the media prefer PCVX or PHVS?

In the previous week, Vaxcyte had 4 more articles in the media than Pharvaris. MarketBeat recorded 12 mentions for Vaxcyte and 8 mentions for Pharvaris. Vaxcyte's average media sentiment score of 1.77 beat Pharvaris' score of 0.94 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pharvaris 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PHVS or APGE?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Apogee Therapeutics N/A N/A -$255.84M -$4.34 N/A

Is PHVS or APGE more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Apogee Therapeutics N/A -29.88% -28.08%

Does the media refer more to PHVS or APGE?

In the previous week, Apogee Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 9 mentions for Apogee Therapeutics and 8 mentions for Pharvaris. Apogee Therapeutics' average media sentiment score of 1.52 beat Pharvaris' score of 0.94 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, PHVS or ALKS?

Alkermes has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Alkermes $1.48B 5.59 $241.66M $0.38 129.37

Is PHVS or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Pharvaris' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to PHVS or ALKS?

In the previous week, Pharvaris had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Pharvaris and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.19 beat Pharvaris' score of 0.94 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PHVS or IBRX more profitable?

Pharvaris has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% ImmunityBio -598.55% N/A -51.65%

Does the media favor PHVS or IBRX?

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. ImmunityBio's average media sentiment score of 0.95 beat Pharvaris' score of 0.94 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Pharvaris (PHVS) Competitors

$37.00 -0.23 (-0.62%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$37.02 +0.02 (+0.05%)

As of 07:39 AM Eastern

Compare

PHVS vs. IMVT, PCVX, APGE, ALKS, and IBRX

Should you buy Pharvaris stock or one of its competitors? Pharvaris's main competitors and comparable companies include Immunovant (IMVT), Vaxcyte (PCVX), Apogee Therapeutics (APGE), Alkermes (ALKS), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharvaris compare to Immunovant?

Pharvaris (NASDAQ:PHVS) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Immunovant is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Pharvaris currently has a consensus price target of $51.08, indicating a potential upside of 38.05%. Immunovant has a consensus price target of $44.00, indicating a potential upside of 0.25%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Pharvaris' return on equity of -61.40% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Immunovant	N/A	-69.59%	-62.49%

47.1% of Immunovant shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. Immunovant's average media sentiment score of 1.29 beat Pharvaris' score of 0.94 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a beta of -2.31, meaning that its share price is 331% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Pharvaris beats Immunovant on 9 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 40.78%. Pharvaris has a consensus target price of $51.08, suggesting a potential upside of 38.05%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, indicating that its share price is 331% less volatile than the broader market.

In the previous week, Vaxcyte had 4 more articles in the media than Pharvaris. MarketBeat recorded 12 mentions for Vaxcyte and 8 mentions for Pharvaris. Vaxcyte's average media sentiment score of 1.77 beat Pharvaris' score of 0.94 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pharvaris	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte's return on equity of -37.56% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Pharvaris	N/A	-61.40%	-56.00%

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vaxcyte beats Pharvaris on 8 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Apogee Therapeutics?

Pharvaris (NASDAQ:PHVS) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

79.0% of Apogee Therapeutics shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Apogee Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 9 mentions for Apogee Therapeutics and 8 mentions for Pharvaris. Apogee Therapeutics' average media sentiment score of 1.52 beat Pharvaris' score of 0.94 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharvaris currently has a consensus target price of $51.08, suggesting a potential upside of 38.05%. Apogee Therapeutics has a consensus target price of $124.43, suggesting a potential downside of 7.79%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20

Pharvaris has a beta of -2.31, indicating that its stock price is 331% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Apogee Therapeutics' return on equity of -29.88% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Summary

Apogee Therapeutics beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Alkermes?

Pharvaris (NASDAQ:PHVS) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Pharvaris had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Pharvaris and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.19 beat Pharvaris' score of 0.94 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Alkermes	$1.48B	5.59	$241.66M	$0.38	129.37

Alkermes has a net margin of 3.96% compared to Pharvaris' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Alkermes	3.96%	4.15%	2.19%

95.2% of Alkermes shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharvaris has a beta of -2.31, suggesting that its stock price is 331% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Pharvaris currently has a consensus target price of $51.08, indicating a potential upside of 38.05%. Alkermes has a consensus target price of $54.56, indicating a potential upside of 10.99%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Summary

Alkermes beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Pharvaris compare to ImmunityBio?

Pharvaris (NASDAQ:PHVS) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. ImmunityBio's average media sentiment score of 0.95 beat Pharvaris' score of 0.94 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
ImmunityBio	-598.55%	N/A	-51.65%

8.6% of ImmunityBio shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pharvaris has higher earnings, but lower revenue than ImmunityBio. Pharvaris is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
ImmunityBio	$113.29M	77.18	-$351.40M	-$0.97	N/A

Pharvaris has a beta of -2.31, indicating that its share price is 331% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Pharvaris currently has a consensus price target of $51.08, suggesting a potential upside of 38.05%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 72.12%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

ImmunityBio beats Pharvaris on 10 of the 15 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.44B	$4.05B	$7.40B	$12.81B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-12.13	11.42	272.22	24.11
Price / Sales	N/A	1,318.55	616.80	85.74
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	6.92	16.83	13.13	6.20
Net Income	-$198.79M	-$22.76M	$3.47B	$348.07M
7 Day Performance	1.68%	2.95%	1.87%	1.02%
1 Month Performance	8.92%	11.17%	8.05%	4.20%
1 Year Performance	55.59%	57.34%	26.01%	16.46%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.7955 of 5 stars	$37.00 -0.6%	$51.08 +38.0%	+54.2%	$2.44B	N/A	N/A	30	Short Interest Increase
IMVT Immunovant	1.0252 of 5 stars	$44.30 +1.3%	$44.00 -0.7%	+191.0%	$9.15B	N/A	N/A	120	News Coverage Positive News Analyst Forecast
PCVX Vaxcyte	2.5162 of 5 stars	$59.79 -0.7%	$86.00 +43.8%	+102.0%	$8.90B	N/A	N/A	160	Positive News
APGE Apogee Therapeutics	1.6571 of 5 stars	$134.57 0.0%	$124.43 -7.5%	+256.4%	$8.37B	N/A	N/A	91	News Coverage Positive News
ALKS Alkermes	2.268 of 5 stars	$49.48 -0.7%	$54.56 +10.3%	+69.6%	$8.30B	$1.48B	130.21	2,050	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors

PHVS vs. IMVT, PCVX, APGE, ALKS, and IBRX

How does Pharvaris compare to Immunovant?

Summary

How does Pharvaris compare to Vaxcyte?

Summary

How does Pharvaris compare to Apogee Therapeutics?

Summary

How does Pharvaris compare to Alkermes?

Summary

How does Pharvaris compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharvaris (PHVS) Competitors

PHVS vs. IMVT, PCVX, APGE, ALKS, and IBRX

How does Pharvaris compare to Immunovant?

Which has higher earnings and valuation, PHVS or IMVT?

Do analysts rate PHVS or IMVT?

Is PHVS or IMVT more profitable?

Do insiders & institutionals have more ownership in PHVS or IMVT?

Does the media prefer PHVS or IMVT?

Which has more risk & volatility, PHVS or IMVT?

Summary

How does Pharvaris compare to Vaxcyte?

Which has stronger earnings & valuation, PCVX or PHVS?

Do analysts recommend PCVX or PHVS?

Which has more risk & volatility, PCVX or PHVS?

Does the media prefer PCVX or PHVS?

Is PCVX or PHVS more profitable?

Do insiders & institutionals hold more shares of PCVX or PHVS?

Summary

How does Pharvaris compare to Apogee Therapeutics?

Which has stronger valuation & earnings, PHVS or APGE?

Do institutionals and insiders have more ownership in PHVS or APGE?

Does the media refer more to PHVS or APGE?

Do analysts rate PHVS or APGE?

Which has more volatility and risk, PHVS or APGE?

Is PHVS or APGE more profitable?

Summary

How does Pharvaris compare to Alkermes?

Does the media refer more to PHVS or ALKS?

Which has preferable earnings & valuation, PHVS or ALKS?

Is PHVS or ALKS more profitable?

Do institutionals & insiders hold more shares of PHVS or ALKS?

Which has more risk and volatility, PHVS or ALKS?

Do analysts prefer PHVS or ALKS?

Summary

How does Pharvaris compare to ImmunityBio?

Does the media favor PHVS or IBRX?

Is PHVS or IBRX more profitable?

Do insiders & institutionals hold more shares of PHVS or IBRX?

Which has better valuation and earnings, PHVS or IBRX?

Which has more risk and volatility, PHVS or IBRX?

Do analysts rate PHVS or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools